943595-13-9

Basic information

• Product Name: Benzoic acid, 2-(broMoMethyl)-6-Methoxy-, Methyl ester
• Synonyms: Benzoic acid, 2-(broMoMethyl)-6-Methoxy-, Methyl ester;2-Bromomethyl-6-methoxy-benzoic acid methyl ester;Methyl 2-(bromomethyl)-6-methoxybenzoate
• CAS NO: 943595-13-9
• Molecular Formula: C₁₀H₁₁BrO₃
• Molecular Weight: 259.09654
• Mol File: 943595-13-9.mol
• Article Data: 12

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: Benzoic acid, 2-(broMoMethyl)-6-Methoxy-, Methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Benzoic acid, 2-(broMoMethyl)-6-Methoxy-, Methyl ester(943595-13-9)
• EPA Substance Registry System: Benzoic acid, 2-(broMoMethyl)-6-Methoxy-, Methyl ester(943595-13-9)

Safety Data

• Hazardous Substances Data: 943595-13-9(Hazardous Substances Data)

Usage

General Description

Benzoic acid, 2-(bromoMethyl)-6-Methoxy-, Methyl ester is a chemical compound that is commonly used as a flavoring agent in food and beverages. It is also used in the production of fragrances, pharmaceuticals, and as a chemical intermediate in organic synthesis. Benzoic acid, 2-(broMoMethyl)-6-Methoxy-, Methyl ester is a methyl ester derivative of benzoic acid and contains a bromomethyl group and a methoxy group. It is important to handle this chemical with caution as it can be harmful if ingested or inhaled, and can cause irritation to the skin and eyes. Additionally, it is important to follow proper safety procedures when working with this compound to avoid any potential hazards.

Upstream product

• 567-61-3 2-hydroxy-6-methylbenzoic acid 
• 4389-50-8 2-amino-6-methylbenzoic acid 
• 13506-76-8 2-methyl-6-nitrobenzoic acid 
• 6161-65-5 2-methoxy-6-methyl-benzoic acid 
• 79383-44-1 methyl 2-methyl-6-methoxybenzoate 

Downstream Products

• 1213268-09-7 methyl 2-{(benzo[d]thiazol-2-ylthio)methyl}-6-methoxybenzoate 
• 104156-21-0 2-[2-(3-Carboxymethyl-phenyl)-ethyl]-6-methoxy-benzoic acid methyl ester 
• 104156-22-1 3-<2-(2-carboxy-3-methoxyphenyl)ethyl>phenylacetic acid 
• 104156-23-2 2-[2-(3-Chlorocarbonylmethyl-phenyl)-ethyl]-6-methoxy-benzoyl chloride 
• 104156-20-9 2-[(Z)-2-(3-Carboxymethyl-phenyl)-vinyl]-6-methoxy-benzoic acid methyl ester 
• 480-47-7 hydrangenol 
• 960506-47-2 diethyl {[2-(tert-butyldimethylsilyloxy)methyl]-3-methoxybenzylsulfonyl}methylphosphonate 
• 960506-46-1 diethyl [(2-hydroxymethyl)-3-methoxybenzylsulfonyl]methylphosphonate 
• 960506-52-9 C₁₄H₂₃SPO₅ 
• 857652-04-1 2-(bromomethyl)-6-methoxybenzyl alcohol 
• 82780-51-6 (+/-)-3-(4-methoxyphenyl)-8-methoxy-3,4-dihydroisocoumarin 
• 104172-27-2 (2-carbomethoxy-3-methoxybenzyl)triphenylphosphonium bromide 

Relevant articles and documents

TREATING LONG QT SYNDROME

This document relates to compounds useful for treating and preventing disorders associated with long QT syndrome such as cardiac arrhythmia, ventricular arrhythmia, hypertrophic cardiomyopathy, and congestive heart failure. Also provided herein are methods and materials for using such compounds to shorten myocardial repolarization time in a patient.

Assessment of the regioselectivity in the condensation reaction of unsymmetrical o-phthaldialdehydes with alanine

One approach for the synthesis of isoindolinones, a privileged bioactive heterocyclic core structure, involves a condensation reaction of o-phthaldialdehydes with a suitable nitrogen-containing nucleophile. This fascinating reaction is revisited here in the context of the use of o-phthaldialdehydes that contain additional substituents in the aromatic ring leading to a detailed analysis of the regioselectivity of the reaction. Eleven monosubstituted o-phthaldialdehydes were synthesised and reacted with alanine. The regioselectivity observed across the eleven substrates led to the design of a disubstituted substrate that reacted with very high control. A gram-scale reaction followed by esterification gave one major regioisomer in high yield. In addition, the regioselectivity observed on reaction of two novel monodeuterated substrates led to an increased mechanistic understanding.

HISTONE ACETYLTRANSFERASE ACTIVATORS AND USES THEREOF

The invention provides compounds and compositions comprising compounds that modulate histone acyl transferase (HAT). The invention further provides methods for treating neurodegenerative disorders, conditions associated with accumulated amyloid-beta peptide deposits, Tau protein levels, and/or accumulations of alpha-synuclein as well as cancer by administering a compound that modulates HAT to a subject.